Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P05019
UPID:
IGF1_HUMAN
Alternative names:
Mechano growth factor; Somatomedin-C
Alternative UPACC:
P05019; B2RWM7; E9PD02; P01343; Q14620
Background:
Insulin-like growth factor I, also known as Somatomedin-C or Mechano growth factor, plays a pivotal role in growth, glucose metabolism, and synapse maturation. It acts primarily by binding to its receptor, IGF1R, initiating signaling pathways crucial for cellular processes. Its unique ability to stimulate glucose transport and glycogen synthesis in osteoblasts distinguishes it from insulin, highlighting its significance in bone development.
Therapeutic significance:
The association of Insulin-like growth factor I with Insulin-like growth factor I deficiency, a disorder marked by growth retardation, sensorineural deafness, and intellectual disability, underscores its therapeutic potential. Understanding the role of Insulin-like growth factor I could open doors to potential therapeutic strategies for addressing not only growth disorders but also metabolic and neurological conditions.